GTBP
GT Biopharma, Inc.
Key Financials
Operating Income
$-12422000
↓ 82.0%
Net Income
$-28354000
↓ 25.2%
Gross Profit
$0
NaN%
Shareholders' Equity
$5.8M
↑ 92.9%
Total Assets
$8.1M
↑ 87.6%
Total Liabilities
$1.3M
↓ 95.7%
Cash & Equivalents
$6.8M
↑ 72.4%
Revenue
$0
NaN%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| PRE 14A | 10/2/2026 | View on SEC |
| D | 9/29/2026 | View on SEC |
| 8-K | 9/25/2026 | View on SEC |
| 8-K | 9/21/2026 | View on SEC |
| SCHEDULE 13G | 9/15/2026 | View on SEC |
| 8-K | 9/15/2026 | View on SEC |
| 8-K | 9/3/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| DEF 14A | 7/2/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GTBP |
| Company Name | GT Biopharma, Inc. |
| CIK | 109657 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (800) 304-9888 |